Welcome to our dedicated page for CLBS news (Ticker: CLBS), a resource for investors and traders seeking the latest updates and insights on CLBS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CLBS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CLBS's position in the market.
Caladrius Biosciences, a clinical-stage biopharmaceutical company (Nasdaq: CLBS), will have its President and CEO, David J. Mazzo, present at the Zooming with LD virtual event on July 29, 2021, at 10:00am PT. The event aims to connect micro-cap companies with investors, featuring a live webcast accessible via the company’s website. Caladrius focuses on cellular therapies to reverse diseases, with product candidates including CLBS16, CLBS12, CLBS201, and OLOGO™.
Caladrius Biosciences has received FDA authorization for its new IND application to study CLBS201, a CD34+ cell therapy targeting diabetic kidney disease (DKD). The upcoming phase 1/2 proof-of-concept study aims to evaluate the safety and efficacy of the therapy in patients with reduced kidney function. CEO David J. Mazzo indicated that this development addresses a significant unmet medical need as diabetes and hypertension prevalence rises. Clinical trials are expected to initiate in the coming months.
Caladrius Biosciences (Nasdaq: CLBS) announced that its CEO, Dr. David J. Mazzo, will present at the World Stem Cell Summit on June 17, 2021, at 10:30 a.m. ET. The presentation includes a 20-minute corporate overview and a Q&A session. Interested parties can access the presentation through the summit's registration or the Investor Forum. Caladrius is advancing its cell therapy products, including CLBS16 for coronary microvascular dysfunction, and HONEDRA for Buerger’s Disease, with ongoing clinical trials and designations from various health authorities.
Caladrius Biosciences, Inc. (Nasdaq: CLBS) participates in key industry events, including the NCVH Annual Conference (June 1-4, 2021) in New Orleans, the LD Micro Invitational XI (June 8-10, 2021), and BIO Digital (June 10-11 & 14-18, 2021). Notable attendees include Tariq Imam and David J. Mazzo. The company focuses on cellular therapies to reverse diseases, with ongoing studies for products like CLBS16 for coronary microvascular dysfunction and HONEDRA® for critical limb ischemia. For more information, visit www.caladrius.com.
Caladrius Biosciences (Nasdaq: CLBS) received $1.4 million in non-dilutive funding from the New Jersey Economic Development Authority's Technology Business Tax Certificate Transfer Program. This achievement enables the company to convert its New Jersey net operating losses into funding, totaling over $12 million cumulatively. Alongside this funding, Caladrius has raised $90 million in public markets in 2021, supporting the advancement of its CD34+ cell therapy pipeline, including ongoing studies for treatments such as CLBS16 and CLBS12.
Caladrius Biosciences (Nasdaq: CLBS) reports significant advancements in its clinical pipeline and a robust financial position as of March 31, 2021. The company is conducting the Phase 2b FREEDOM Trial for CLBS16, targeting coronary microvascular dysfunction, and aims to complete patient enrollment by year-end 2021. Ongoing studies for HONEDRA® in Japan are progressing, albeit impacted by COVID-19. Caladrius also plans to initiate a Phase 2 study for CLBS201 in diabetic kidney disease. Financially, the company recorded a net loss of $8.1 million but possesses approximately $111.5 million in cash, ensuring operational continuity through several key trials.
Caladrius Biosciences, a clinical-stage biopharmaceutical company focused on cellular therapies, announced participation in key industry and investor events occurring in May 2021. These include the BioEquity Europe Digital from May 17-19, BioNJ’s 11th Annual BioPartnering Conference from May 18-19, and the Advanced Therapies Congress & Expo from May 19-21. The company is advancing several treatments including CLBS16, HONEDRA, CLBS201, and OLOGO, targeting conditions like coronary microvascular dysfunction and critical limb ischemia.
Caladrius Biosciences, Inc. (Nasdaq: CLBS) will report its financial results for Q1 2021 on May 6, 2021, at 4:30 p.m. ET. Investors can join the conference call using the provided dial-in numbers, or view a live webcast on the company’s website. The company focuses on cellular therapies aimed at reversing disease, with key products including CLBS16, HONEDRA® (CLBS12), CLBS201, and OLOGO™ (CLBS14). These products are in various stages of clinical development targeting conditions like coronary microvascular dysfunction, Buerger’s Disease, diabetic kidney disease, and disabling angina.
On March 8, 2021, Caladrius Biosciences (Nasdaq: CLBS) announced that the FDA has granted orphan drug designation to its CD34+ cell therapy, CLBS12, for treating Buerger’s disease, a condition with no current approved treatment in the U.S. This designation aids in expediting the development and potential approval process, offering incentives like tax credits. Preliminary results from ongoing studies in Japan show 60% of subjects achieving a positive outcome for chronic limb ischemia (CLI) and Buerger’s disease. This marks a significant step towards addressing a critical unmet medical need.
BASKING RIDGE, N.J., March 3, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) announces its participation in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. The company will present an overview and hold virtual investor meetings. Investors can register via the provided link. Caladrius focuses on developing cellular therapies aimed at reversing diseases, with products like CLBS16 and HONEDRA® currently in clinical trials. For more information, visit www.caladrius.com.
FAQ
What is the market cap of CLBS (CLBS)?
